ADRB2 and neoplasm: Increased glycolytic activity by inhibiting β2-AR signaling might be due to the increased expression of co-stimulatory molecules and decreased expression of co-inhibitory molecules on the surfaces of tumor-infiltrating lymphocytes [52,53].